SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: yosarian_2 who wrote (3974)11/4/2015 7:21:07 PM
From: Biomaven1 Recommendation

Recommended By
tktom

   of 4474
 
You have to be realistic about the value of any pre-clinical drug in this class. Lots of potential toxicity, and so even fantastic pre-clinical results will not necessarily translate into immediate stock price appreciation.

It's quite unclear how much EGFR resistance in practice stems from inadequate inhibitors or other (downstream) factors. Overall this is obviously a very big market, but a lot will depend on the actual characteristics of any drug, some of which will only be revealed in the clinic.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News